Haemonetics Corp: discloses supply agreement with CSL Plasma

What happened

• On Aug 18, 2026, Haemonetics Corporation furnished a Current Report on Form 8-K disclosing its entry into a non-exclusive supply agreement with CSL Plasma Inc., under which CSL may utilize the Company’s NexSys PCS® devices with Persona® PLUS technology and purchase related disposables in the United States.
• On Oct 8, 2026, CSL announced that it expects to complete the rollout of Haemonetics’ devices and disposables under the supply agreement by the end of calendar year 2027 and informed Haemonetics that it currently anticipates the transition will occur at all of CSL’s current U.S. plasma collection centers.

Key details

• Initial 8-K furnished: Aug 18, 2026.
• CSL announcement date: Oct 8, 2026.
• Rollout expected by: end of calendar year 2027.
• Haemonetics is not updating its previously issued fiscal 2027 guidance and expects to provide an update on the anticipated impact on fiscal 2027 financial results on its 2nd fiscal quarter earnings call in Nov 2026.

Why it may matter

• This item was reported under Item 7.01 (Regulation FD disclosure), which covers public disclosure of material information; the filing describes the supply agreement and CSL’s announced rollout plan while noting scope and timing remain subject to change and implementation details are to be determined by CSL and Haemonetics.
• This filing does not show why the insider traded or why the company acted.